Small Cell Carcinoma with Paraneoplastic Polyneuropathy and Tumor Embolization: A Case Report and Literature Review

Manica Sodhi b James K. Stoller a, c

a Respiratory Therapy, b Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, and c Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA

Established Facts

- Paraneoplastic sensory polyneuropathy with anti-Hu antibodies is an uncommon manifestation of cancer which is most frequently associated with small cell carcinoma.
- Available estimates suggest that fewer than 1% of all neoplasms and 4% of small cell cancers are complicated by paraneoplastic sensory polyneuropathy.

Novel Insights

- This patient represents only the second individual to be described with tumor embolization complicating small cell cancer and reminds clinicians of the extended spectrum of this disease.

Key Words
Small cell cancer · Tumor embolism · Sensory polyneuropathy · Anti-Hu antibodies

Abstract

Although small cell cancer of the lung may have protean manifestations, tumor embolization and inability to identify the primary sites are unusual features. We present a patient with anti-Hu antibody-associated paraneoplastic sensory polyneuropathy and tumor embolism diagnosed by endovascular biopsy to be due to small cell cancer, the primary site of which was not evident. To our knowledge, this patient represents only the second individual to be described with tumor embolization complicating small cell cancer and reminds clinicians of the extended spectrum of this disease.

Introduction

Paraneoplastic sensory polyneuropathy (PSP) with anti-Hu antibodies (AHA) is an uncommon manifestation of cancer [1, 2] which is most frequently associated with small cell carcinoma (SCC) [3, 4]. Hematogenous embolization is another uncommon complication of
cancer [5–7] which is rare in the setting of SCC [8]. To
demonstrate several unusual features of SCC, this report
describes a woman who presented with a polyneuropa-
thy and superior vena cava (SVC) syndrome and was
found to have AHA and hematogenous embolization of
SCC.

Case Report

A 52-year-old woman was transferred to the Cleveland Clinic
with a 10-month history of hyperesthesia of the extremities and
more recent facial swelling.

On physical examination, she had facial fullness. Her chest
was clear, cardiac and abdominal examinations were unremark-
able, and she had no palpable lymphadenopathy. Extremities
showed no cyanosis, clubbing or edema. Neurological examina-
tion showed marked hyperesthesia of all extremities from the
ankles to the knees and from her fingers to her elbows.

Laboratory evaluation showed normal complete blood count
and electrolytes. Outside studies included a chest X-ray showing
a right paratracheal mass and calcified parenchymal granuloma-
ta. Before transfer, MRI of the brain and spine showed no masses
and small disk herniations (T7–8 and L5–S1). Chest CT (fig. 1)
showed an intraluminal filling defect (extending from the junc-
tion of the innominate veins through the SVC to the level of the
right atrium) and extensive chest wall collateral vessels. Also,
there was retrocaval, right paratracheal and subcarinal lymph-
adenopathy (some calcified), ranging from 15 to 30 mm in diam-
eter but no parenchymal masses other than calcified granuloma-
ta. Abdominal CT showed no findings suggesting neoplasm. On
suspicion of polyneuropathy, workup included a paraneoplastic
antibody panel which showed elevated AHA titers but was other-
wise negative. Bronchoscopy showed a normal endobronchial ex-
amination. An endovascular biopsy of the filling defect in the
innominate veins (fig. 1) showed SCC (fig. 2).

The patient elected early discharge to seek treatment closer to
home.

Discussion

This patient extends the spectrum of described mani-
festations of SCC in demonstrating both anti-Hu PSP and
hematogenous embolization.

Unusual features of our patient’s illness include: (1) the
presence of PSP due to onconeural antibodies, which has
been described in only 1.7% of patients evaluated for neu-
ropathy [1], (2) an atypical presentation of SCC given the
absence of either pulmonary parenchymal or airway ab-
normalities, and (3) demonstration of tumor emboliza-
tion by endovascular biopsy in the context of the SVC
syndrome.
Paraneoplastic neurologic syndromes are caused by autoimmune processes triggered by the cancer and directed against antigens (called ‘onconeural antigens’) that are common to both the cancer and the nervous system. Such syndromes can affect any part of the central and peripheral nervous system, the neuromuscular junction and muscle and include: Lambert-Eaton myasthenic syndrome, subacute cerebellar ataxia, limbic encephalitis, opsoclonus – myoclonus, retinopathies, sensory neuropathies, encephalomyelitis and dermatomyositis. Among these paraneoplastic neurologic syndromes, the most common is PSP, which accounts for 31–54% of instances [1, 2]. PSP is an uncommon complication of cancer, with available estimates suggesting that fewer than 1% of all neoplasms [3] and 4% of SCCs [4] are complicated by PSP. Classic clinical manifestations of PSP at onset are pain and paresthesias with asymmetric distribution that involve the arms. Later, pain may be replaced by numbness, limb ataxia and pseudoathetotic movements of the limbs [5].

AHA (i.e. antibodies that are part of a family of RNA-binding proteins – HuD, HuC, Hel-N1, Hel-N2 – which are expressed in the nuclei of neurons and in cancer cells) account for most cases of PSP [1, 8]; furthermore, lung SCC accounts for most [3, 4] cancers associated with AHA (66–78%). Other neoplasms (e.g., prostate, adrenal) [1] are less frequently associated with AHA.

Lung SCC typically arises in the central airways, infiltrating the submucosa and gradually obstructing the bronchial lumen through extrinsic or endobronchial spread. A radiographic presentation as a hilar mass with bulky mediastinal adenopathy is most common. However, notably, individuals with SCC and PSP often experience a long delay between the onset of the neuropathy and initial detection of the tumor (mean 6.5 ± 7.0 months, range 1–47) [1, 4]. In our patient, though available imaging did not identify a primary SCC site, her truncated hospitalization precluded some testing (e.g. positron emission tomography) that might have revealed a primary site.

Finally, tumor embolization is uncommon in lung cancer, estimated to occur in only 10% of cases [6–8]. Tumor embolization with lung SCC is even more rare, with only one single case report available [9]; Wong et al. [9] described a 55-year-old man who developed acute dyspnea and hemodynamic collapse found at postmortem to be due to extensive SCC tumor embolism. A second related case [10] regards a patient with SCC that presented as an intravascular tumor in the left main pulmonary artery, but without reported extravascular extension noted at surgery; this second patient also initially presented with paraneoplastic polyneuropathy.

To our knowledge, our patient represents only the second case of SCC complicated by tumor embolization. In this regard, she extends available experience and reminds clinicians that SCC may have protean manifestations, including PSP and vascular occlusion due to tumor embolization.
References